Biophan's MRI-Safety Technology Named In Harvard Heart Letter Article on MRI Safety and Medical Devices

Business Wire, April 20, 2006

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH)(FWB: BTN), a developer of next-generation medical technology, announced today that the Company's technology for MRI-safe medical devices is mentioned in the April 2006 edition of the Harvard Heart Letter in an article titled "Clash of the titans: The pacemaker and the MRI can't work together - at least not yet," an article dealing with MRI safety and medical devices, in which Biophan is named as one company that has been public about its work in the area of MRI safety. The article is available on Biophan's website at http://www.biophan.com/articles/2006/MRI_HHL.pdf.> Biophan is focused on making biomedical devices that are safe and image compatible under Magnetic Resonance Imaging (MRI). Most pacemakers and neurostimulators are contra-indicated for use under MRI, as this carries potentially fatal side effects to patients. These side effects include the medical device being moved out of position by the magnetic field, energy flow in the lead wire connecting the device to tissue causing heating and scarring, electrical currents causing devices to overly stimulate the heart and unintentional reprogramming of the pacemaker or implantable cardioverter. Other devices such as stents are not image compatible, since they do not create a safety concern for the patient but they interfere with the MR image in the area around the device.

Biophan has a licensing agreement with Boston Scientific for its MRI technology and recently announced a declaration of intent to enter into negotiations for a strategic research collaboration with Siemens' Medical Solutions MRI Division in Europe.

Michael Weiner, CEO of Biophan, said, "MRI is contraindicated for many biomedical devices, preventing many patients with serious medical conditions from the benefits of this powerful diagnostic tool. Many major medical publications in the U.S. and internationally have recognized this as a serious problem. We are pleased that The Harvard Heart Letter, a well-respected and prestigious publication, has recognized our MRI-safe technology and its importance for patients who have implanted medical devices that are contraindicated for use with MRI. Biophan will continue to develop and license this important technology with the goal of making all implantable devices MRI safe and image compatible so that patients will be able to receive the best medical attention."

About Harvard Health Publications

Harvard Health Publications is a division of the Harvard Medical School. The goal of all of their publications is to bring the public, around the world, the most current practical, authoritative health information, drawing on the expertise of the 8,000 faculty physicians at the Harvard Medical School and its world-famous affiliated hospitals.

Working with partners in the publishing industry, Harvard Health Publications publishes information about health and wellness through all types of media: newsletters, books, and our website (www.health.harvard.edu). In addition, Harvard Health Publications has editorial responsibility for one of the world's largest and most heavily visited consumer health websites: InteliHealth. Their mission is to be the world's most widely recognized and trusted provider of high-quality information about health. Harvard Medical School does not endorse any particular products.

About Biophan

Biophan develops and markets cutting-edge technologies for the medical device industry that provide competitive advantages. The Company's founding goal was to make all biomedical devices capable of safely and successfully working with magnetic resonance imaging (MRI), problems which the Company has solved and begun to license to leading device manufacturers. The Company's mission has expanded to provide other technologies which will improve the delivery of healthcare. Biophan's technologies enable medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and implants such as stents to be safely and/or effectively imaged under MRI. The Company is helping to commercialize the MYO-VAD(TM), a novel, MRI-compatible ventricular assist device which has significant potential to improve the treatment of many forms of acute and chronic heart disease. Other applications in development include drug delivery and power systems which derive energy from body heat. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications, plus international applications. This total includes 50 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 98 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials, and photonics. Biophan has joint development and licensing agreements with Boston Scientific Corporation and NASA's Ames Center for Nanotechnology. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN.